论文部分内容阅读
为提高BCG的免疫效果,以BCG进行初次免疫,比较pHSP65基因疫苗和BCG疫苗加强免疫的效果,寻找新型结核疫苗的初免-加强免疫策略。于第0周皮下接种BCG,第6、8周给予pHSP65滴鼻免疫或BCG加强免疫,末次免疫后2周检测全身及肺脏局部IFN-γ的产生。与BCG初免/BCG加强免疫相比,经pHSP65基因疫苗滴鼻加强免疫后,ELISPOT结果显示脾脏和肺局部分泌IFN-γ的淋巴细胞数量显著增加,流式检测显示IFN-γ+CD4+T细胞数量显著增加,ELISA结果证实淋巴细胞IFN-γ的分泌显著增高,提示经BCG初次免疫后,以pHSP65 DNA滴鼻加强免疫可显著增强全身和肺局部T淋巴细胞IFN-γ的产生,具有良好的抗结核感染潜能。
In order to improve the immune effect of BCG, the primary immunization with BCG was carried out to compare the effect of pHSP65 gene vaccine and BCG vaccine in boosting immunity and to find the prime-boost immunization strategy of new tuberculosis vaccine. BCG was inoculated subcutaneously on week 0, and pHSP65 nasal or BCG was boosted on the 6th and 8th week. Whole body and lung IFN-γ production was detected 2 weeks after the last immunization. Compared with BCG prime / BCG booster immunization, ELISPOT results showed that the number of lymphocytes secreting IFN-γ in spleen and lung increased significantly after immunization with pHSP65 gene nasal vaccine. Flow cytometry showed that IFN-γ + CD4 + T The number of cells increased significantly. The results of ELISA showed that the secretion of IFN-γ in lymphocytes was significantly increased, suggesting that immunization with pHSP65 DNA nasal drops could significantly enhance the IFN-γ production of T lymphocytes in the whole body and lung after BCG primary immunization. Anti-TB infection potential.